MATRIX(Migrainer Assess TRiptane eXamination)

MATRIX(Migrainer Assess TRiptane eXamination) - MATRIX

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003063

Enrollment

100

Registered

2010-01-20

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

sumatriptan eletriptan zolmitriptan rizatriptan naratriptan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as migraine

Exclusion criteria

Exclusion criteria: Ischemic heart disease, old age, medication overuse headache

Design outcomes

Primary

Measure	Time frame
Effect of Triptane medication evaluated wtih VAS and SF36	—

Secondary

Measure	Time frame
Side effect of Triptane Relation of VAS and SF36	—

Countries

Japan

Contacts

Public ContactYasushi Shibata

University of Tsukuba Department of Neurosurgery

029-231-2371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026